Abstract
Background: Neo-angiogenesis seems to be a critical feature of breast tumor growth, migration and metastasis. Inhibition of angiogenesis may provide information regarding treatment. Since angiogenesis is the result of complex processes, controlled by several angiogenic (pro- and/ or -anti) factors and their receptors, multiple ways to prevent or retrogress tumor-induced angiogenesis have been proposed. The clinically significant activity of bevacizumab and other antiangiogenic treatments have attracted a great deal of interest. Objective/methods: We discuss biological aspects of breast cancer angiogenesis and nucleoside diphosphate kinase (NDPK) as a key molecule in this process. Results/conclusions: In clinical and experimental trials, it was reported that NDPK is inversely related to breast cancer metastasis and angiogenesis. To inhibit the metastatic potential of cancer cells, Nm23-H1/NDP kinase appears to interact with many proteins involved in cellular signal transduction in angiogenesis and tumorigenesis, and therefore reduces the activation of the extracellular signal-regulated kinase (ERK)/MAPK in response to those signals.
Original language | English |
---|---|
Pages (from-to) | 1419-1430 |
Number of pages | 12 |
Journal | Expert Opinion on Therapeutic Targets |
Volume | 12 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2008 Nov |
Bibliographical note
Funding Information:This work was in part by 0520040-1 Cancer Research Grant, KOSEF 2006-02293 Grant & Pusan National University Research Grant, 2008.
Keywords
- Angiogenesis
- Breast cancer
- Nm23-H1/NDP
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Clinical Biochemistry